On February 28, 2025, Alzamend Neuro Inc. amended its bylaws to lower the quorum requirement for stockholder meetings from a majority to 35%, and filed a Certificate of Designations for its Series C Convertible Preferred Stock, which includes terms for an exchange and sale of shares with an investor.